GlassScriptPhysician profile
Namra W Butt
NPI 1861855504
$3,400.52
in general payments reported to CMS, 2019-2025
23 companies · $954 in 2025
The $954 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $439 · 2020: $235 · 2021: $608 · 2022: $521 · 2023: $331 · 2024: $312 · 2025: $954.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,597.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,597.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $638.85 | 2019-2025 | Eluvia, Ekosonic |
| Abbott Laboratories | $502.50 | 2019-2025 | Cardiomems |
| Amgen INC. | $423.82 | 2022-2025 | Repatha, Repatha |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $317.09 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $225.39 | 2019-2025 | |
| Regeneron Pharmaceuticals, INC. | $197.86 | 2025 | Evkeeza |
| Esperion Therapeutics, INC. | $192.15 | 2024-2025 | Nexletol |
| Janssen Pharmaceuticals, INC | $186.04 | 2019-2021 | |
| United Therapeutics Corporation | $124.99 | 2021 | |
| Novo Nordisk INC | $111.77 | 2025 | Ozempic |
| E.R. Squibb & Sons, L.L.C. | $84.83 | 2025 | Camzyos, Eliquis |
| Philips North America LLC | $81.65 | 2022 | |
| Biotronik INC. | $57.18 | 2021-2022 | |
| Bard Peripheral Vascular, INC. | $48.68 | 2023 | Rotarexs 6 F X 135 Cm |
| Asahi Intecc USA, INC. | $37.76 | 2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Terumo Medical Corporation | $34.72 | 2022 | |
| Heartflow, INC. | $25.65 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $21.52 | 2025 | Farxiga |
| Edwards Lifesciences Corporation | $20.33 | 2021 | |
| Getinge USA Sales, LLC | $19.40 | 2019 | |
| Zoll Circulation INC | $18.95 | 2019 | |
| Medtronic, INC. | $15.09 | 2022 | |
| Ekos Corporation | $14.30 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Namra Butt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.